As the number of breast cancer survivors grows, so does the emphasis on establishing individualized survivorship plans
Preoperative neoadjuvant systemic therapy can be valuable for patients even if they do not achieve a pathologic complete response
With thousands of clinical trials in play, many oncology specialists are reluctant to embrace findings from newly-released studies
Should genomic profiles be used routinely to determine which breast cancer patients receive adjuvant chemotherapy
Personalized treatment in oncology is a popular concept these days, but the goal remains elusive
It is time to rethink the way oncologists in the United States are treating ductal carcinoma in situ
The addition of sorafenib to capecitabine as a first-line therapy for patients with advanced breast cancer
The climate for medical malpractice litigation in breast cancer treatment seems to be worsening
Breast pain is among the most common reasons that women seek medical attention from a breast specialist.